MBX Biosciences, Inc.

MBX

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001776111


None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $385.1M
Warnings	dilution, thin data not computable: degenerate inputs, fortress balance sheet
Inputs computable	5 of 14
Graded from	filings received through Mar 12, 2026 242 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026
Last close	$51.43 2026-11-06; market equity $2.5B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 12, 2026

We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide? ("PEP?") platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 75.8						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing					
Accruals ratio	(2.1%)	(6.6%)	75.8	802	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 6.4					
Twelve-month failure probability	0.03%	0.08%	14.9	249	2026-06-30
Altman Z double-prime	26.97	(0.37)	1.5	747	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	24.62x	2.94x	2.9	828	2025-12-31
Growth and financing, sleeve percentile 73.1					
Revenue growth, three-year compound	not computable	10.0%			
four annual observations are required; found 0					
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 2					
Reinvestment rate	not computable	37.1%			
NOPAT must exceed $100,000					
Asset growth, three years	not computable	2.2%			
four annual observations are required; found 2					
Net share issuance, one year	42.1%	2.5%	73.1	630	2026-03-06

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 42.1%
Thin data	5 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-06 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	166.9%	(2.1%)	95
Distance from 52-week high	(27.4%)	(30.4%)	52
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(3.3%)	(1.0%)	44
Book value to price	0.17	0.29	35
Sales to price	not computable	0.30	
Composite equity issuance, five years	not computable	20.8%	
Relative strength against the sector, log excess return	0.81	(0.19)	95

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$54.1M
Operating cash flow, four quarters	-$82.7M
Months of runway	7.9
Days since last periodic filing	95 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	$26.1M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$87.0M	2025-12-31	2026-03-12	10-K	26-103121
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$79.9M	2025-12-31	2026-03-12	10-K	26-103121
3	assets	us-gaap:Assets	$385.1M	2025-12-31	2026-03-12	10-K	26-103121
4	assets	us-gaap:Assets	$268.5M	2024-12-31	2026-03-12	10-K	26-103121
5	current assets	us-gaap:AssetsCurrent	$381.5M	2025-12-31	2026-03-12	10-K	26-103121
6	current liabilities	us-gaap:LiabilitiesCurrent	$15.5M	2025-12-31	2026-03-12	10-K	26-103121
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$224.5M	2025-12-31	2026-03-12	10-K	26-103121
8	operating income	us-gaap:OperatingIncomeLoss	-$98.1M	2025-12-31	2026-03-12	10-K	26-103121
9	book equity	us-gaap:StockholdersEquity	$369.2M	2025-12-31	2026-03-12	10-K	26-103121
10	liabilities	us-gaap:Liabilities	$15.9M	2025-12-31	2026-03-12	10-K	26-103121
11	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.9M	2025-12-31	2026-03-12	10-K	26-103121
12	depreciation amortization	us-gaap:Depreciation	$248,000	2025-12-31	2026-03-12	10-K	26-103121
13	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$87.0M	2025-12-31	2026-03-12	10-K	26-103121
14	income tax	us-gaap:IncomeTaxExpenseBenefit	$0	2025-12-31	2026-03-12	10-K	26-103121
15	current assets	us-gaap:AssetsCurrent	$267.3M	2024-12-31	2026-03-12	10-K	26-103121
16	current liabilities	us-gaap:LiabilitiesCurrent	$11.1M	2024-12-31	2026-03-12	10-K	26-103121
17	shares outstanding	dei:EntityCommonStockSharesOutstanding	47,510,243	2026-03-06	2026-03-12	10-K	26-103121
18	shares outstanding	dei:EntityCommonStockSharesOutstanding	33,424,371	2025-03-13	2025-03-17	10-K	25-039838

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.